ProQR Therapeutics (NASDAQ:PRQR) Posts Earnings Results, Misses Expectations By $0.01 EPS

ProQR Therapeutics (NASDAQ:PRQR) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01), FiscalAI reports. The firm had revenue of $5.50 million for the quarter, compared to the consensus estimate of $6.12 million. ProQR Therapeutics had a negative net margin of 273.20% and a negative return on equity of 58.70%.

ProQR Therapeutics Stock Up 5.5%

PRQR stock traded up $0.10 during trading on Friday, hitting $1.82. The company had a trading volume of 436,113 shares, compared to its average volume of 412,185. The firm has a 50-day moving average price of $1.65 and a 200-day moving average price of $2.07. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $3.10. The stock has a market cap of $190.96 million, a price-to-earnings ratio of -3.88 and a beta of 0.21.

Institutional Investors Weigh In On ProQR Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in PRQR. Ikarian Capital LLC raised its position in shares of ProQR Therapeutics by 67.2% during the fourth quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock worth $3,014,000 after acquiring an additional 600,000 shares during the last quarter. Citadel Advisors LLC increased its position in ProQR Therapeutics by 73.2% in the third quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock worth $1,399,000 after purchasing an additional 277,749 shares during the period. Walleye Capital LLC raised its holdings in ProQR Therapeutics by 11.2% during the 4th quarter. Walleye Capital LLC now owns 591,785 shares of the biopharmaceutical company’s stock worth $1,195,000 after purchasing an additional 59,808 shares during the last quarter. Millennium Management LLC raised its holdings in ProQR Therapeutics by 80.8% during the 4th quarter. Millennium Management LLC now owns 434,991 shares of the biopharmaceutical company’s stock worth $879,000 after purchasing an additional 194,369 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in ProQR Therapeutics by 86.3% during the 3rd quarter. Two Sigma Investments LP now owns 417,300 shares of the biopharmaceutical company’s stock valued at $889,000 after purchasing an additional 193,260 shares during the period. 32.65% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently weighed in on PRQR. Zacks Research raised shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, November 13th. Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a research report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Thursday, January 22nd. Finally, Oppenheimer began coverage on ProQR Therapeutics in a research note on Thursday. They issued an “outperform” rating and a $9.00 price objective on the stock. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.67.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.